



# BILLING AND CODING GUIDE

- Introduction
- Facilitating Coverage and Coding
- Coverage, Coding, and Payment in the Physician Office Setting
- Coverage, Coding, and Payment in the Hospital Outpatient Setting
- Provider Readiness - Process and Tips
- IncyteCARES - Program Overview

Please note this information is provided for your background education and is not intended to serve as guidance for specific coding, billing, and claims submissions. Decisions on which codes best describe the services provided must be made by individual providers based on specific payer guidance and requirements.

Incyte cannot guarantee payment of any claim and providers should contact third-party payers for specific information on their coding, coverage, and payment policies as needed.

**For questions regarding ZYNYZ reimbursement and access, please call IncyteCARES at 1-855-452-5234 Monday through Friday, 8 AM – 8 PM ET.**

# Introduction

**This Billing and Coding Guide is intended to provide an overview of ZYNYZ® (retifanlimab-dlwr) coding and coverage information. Please use this guide to support the reimbursement process and as a source of information on services available through IncyteCARES for ZYNYZ.**

While this guide provides information on navigating the reimbursement process, please note all enclosed coding information is for reference purposes only. Incyte cannot guarantee payment of any claim and providers should contact third-party payers for specific information on their coding, coverage, and payment policies as needed.

**ZYNYZ is indicated for the treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC).**

**This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.**

## IMPORTANT SAFETY INFORMATION

### Severe and Fatal Immune-Mediated Adverse Reactions

Important immune-mediated adverse reactions listed may not be inclusive of all possible severe and fatal immune-mediated reactions.

Immune-mediated adverse reactions, which may be severe or fatal, can occur in any organ system or tissue, can occur at any time after starting or discontinuing treatment with a PD-1/PD-L1-blocking antibody, and can affect more than one body system simultaneously.

Monitor patients closely for symptoms and signs that may be clinical manifestations of such reactions. Early identification and management of immune-mediated adverse reactions are essential to ensure safe use of PD-1/PD-L1-blocking antibodies. Evaluate liver enzymes, creatinine, and thyroid function at baseline and periodically during treatment. If suspected, initiate appropriate workup to exclude alternative etiologies, including infection. Institute medical management promptly, including specialty consultation as appropriate.

Withhold or permanently discontinue ZYNYZ depending on severity. In general, if ZYNYZ requires interruption or discontinuation, administer systemic corticosteroid therapy (1-2 mg/kg/day prednisone or equivalent) until improvement to  $\leq$  Grade 1. Then, initiate corticosteroid taper and continue to taper over at least 1 month. Consider administration of other systemic immunosuppressants in patients whose adverse reactions are not controlled with corticosteroids.

#### Immune-Mediated Pneumonitis

ZYNYZ can cause immune-mediated pneumonitis. Immune-mediated pneumonitis occurred in 3% (13/440) of patients, including fatal (0.2%), Grade 3 (0.9%), and Grade 2 (1.4%) reactions. Pneumonitis led to permanent discontinuation of ZYNYZ in 1 patient and withholding in 0.9%.

Systemic corticosteroids were required in 77% (10/13) of patients. Pneumonitis resolved in 10 of the 13 patients.



# Facilitating Coverage and Coding

## EFFECTIVE OCTOBER 1, 2023, ZYNYZ HAS A UNIQUE J-CODE

**J9345:**  
Injection, retifanlimab-dlwr, 1 mg

The permanent J-code for ZYNYZ is effective for claims on or after October 1, 2023.

Understanding a payer's specific process and instructions is important when submitting a claim for reimbursement as payer requirements regarding detailed claim form information may vary. Please refer to the tips below and always consult a payer's individual policies to ensure you are following their specific requirements.

### What can I do to support timely reimbursement of ZYNYZ claims?

- **Verify accuracy** of patient information
- **Use the ZYNYZ specific J-code:** J9345 (Injection, retifanlimab-dlwr, 1 mg) when completing the 1450 or 1500 Claims Form
- **Refer to the ZYNYZ Billing and Coding Guide** for appropriate codes (e.g., HCPCS, CPT, ICD-10-CM)
  - Special billing instructions may be required in Box 19 of the CMS-1500 Claim Form (Additional Claim Information) to ensure the payer has enough information to adjudicate the claim correctly
- **Include correct number** of units administered
- **Include the correct modifier** - JZ Modifier must be reported for dates of service on or after July 1, 2023 when no product is discarded
- **Ensure accuracy** of the following information needed to process the claim:
  - Correct NDC Format (use 10- or 11-digit format based on payer requirements)
  - Prior Authorization Number (if applicable)
- **Follow the payer's recommendations** for providing additional information (e.g., medical records)
- **Make sure** electronic claims are successfully submitted
- **Stay up to date** with payer coverage policies

The information herein is provided for educational purposes only. Insurance coverage and reimbursement are not guaranteed. Coverage and reimbursement may vary significantly by payer, plan, patient, and setting of care. It is the sole responsibility of the health care provider to select the proper codes and ensure the accuracy of all statements used in seeking coverage and reimbursement for an individual patient.

For Billing and Coding or Reimbursement Questions,  
or to Request Support From a Field Access Manager,  
**Call 1-855-452-5234, M - F 8 AM to 8 PM ET**

**ZYNYZ**<sup>®</sup>  
retifanlimab-dlwr  
Injection 500 mg

# Coverage, Coding, and Payment in the Physician Office Setting

For Medicare patients, ZYNYZ® (retifanlimab-dlwr) will be covered under Medicare Part B when used for an FDA-approved indication and when medically reasonable and necessary. There are no prior authorization requirements for ZYNYZ under traditional fee-for-service Medicare plans.

For patients enrolled in Medicaid, a Medicare Advantage plan, or a commercial health plan, coverage of ZYNYZ will vary by payer. Some payers may also apply utilization restrictions for ZYNYZ.

Incyte cannot guarantee payment of any claim and providers should contact third-party payers for specific information on their coding, coverage, and payment policies as needed.

**Please refer to the table below to support appropriate claims processing for ZYNYZ.**

MCC ICD-10-CM DIAGNOSIS CODES			
<b>C4A0</b>	Merkel cell carcinoma of lip	<b>C4A4</b>	Merkel cell carcinoma of scalp and neck
<b>C4A10</b>	Merkel cell carcinoma of unspecified eyelid, including canthus	<b>C4A51</b>	Merkel cell carcinoma of anal skin
<b>C4A111</b>	Merkel cell carcinoma of right upper eyelid, including canthus	<b>C4A52</b>	Merkel cell carcinoma of skin of breast
<b>C4A112</b>	Merkel cell carcinoma of right lower eyelid, including canthus	<b>C4A59</b>	Merkel cell carcinoma of other part of trunk
<b>C4A121</b>	Merkel cell carcinoma of left upper eyelid, including canthus	<b>C4A60</b>	Merkel cell carcinoma of unspecified upper limb, including shoulder
<b>C4A122</b>	Merkel cell carcinoma of left lower eyelid, including canthus	<b>C4A61</b>	Merkel cell carcinoma of right upper limb, including shoulder
<b>C4A20</b>	Merkel cell carcinoma of unspecified ear and external auricular canal	<b>C4A62</b>	Merkel cell carcinoma of left upper limb, including shoulder
<b>C4A21</b>	Merkel cell carcinoma of right ear and external auricular canal	<b>C4A70</b>	Merkel cell carcinoma of unspecified lower limb, including hip
<b>C4A22</b>	Merkel cell carcinoma of left ear and external auricular canal	<b>C4A71</b>	Merkel cell carcinoma of right lower limb, including hip
<b>C4A30</b>	Merkel cell carcinoma of unspecified part of face	<b>C4A72</b>	Merkel cell carcinoma of left lower limb, including hip
<b>C4A31</b>	Merkel cell carcinoma of nose	<b>C4A8</b>	Merkel cell carcinoma of overlapping sites
<b>C4A39</b>	Merkel cell carcinoma of other parts of face	<b>C4A9</b>	Merkel cell carcinoma, unspecified

  

ZYNYZ DRUG AND ADMINISTRATION CODES			
National Drug Code (NDC)	Drug Administration / CPT Codes	Modifier	HCPCS Code
10-digit: 50881-006-03 11-digit: 50881-0006-03	<b>96413</b> (Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial drug)	<b>JZ</b> (Modifier for recording zero product wastage)	<b>J9345</b> (Injection, retifanlimab-dlwr, 1 mg)

  

PAYMENT METHODOLOGY	
<b>Medicare</b>  Average Sales Price (ASP) +6% <sup>a</sup>	<b>Commercial Payers and Medicaid</b>  Most non-Medicare payers will pay separately for ZYNYZ; however payment rates will vary by payer and provider contract

<sup>a</sup> If Medicare sequestration is in effect, a statutory reduction to the payment is applied. Please visit CMS.gov for more information.



# Coding and Billing Reference Guide

## Example CMS-1500 Claim Form - Physician Office Setting

This example form is provided for guidance and reference only.

ZYNYZ® (retifanlimab-dlwr) and the associated services provided in the physician's office are billed on the CMS-1500 Claim Form or its electronic equivalent. An example CMS-1500 Claim Form is provided below. It is always the provider's responsibility to determine the appropriate healthcare setting, and to submit true and correct claims for the products and services rendered. **Incyte cannot guarantee payment of any claim and providers should contact third-party payers for specific information on their coding, coverage, and payment policies as needed.**

### Box 19

Payers require drug name, route of administration, NDC, and total dosage

Check with your payer to verify specific requirements, including use of the 10-digit or 11-digit NDC

### Box 21

Enter appropriate diagnosis code(s)

### Box 24 A-B

Enter the date of service and the appropriate place of service code

### Box 24 D

Enter the appropriate drug and administration codes, for example:

- Drug - J9345 (Injection, retifanlimab-dlwr, 1 mg), effective 10/01/2023
- Administration - 96413 (chemo infusion for 1st hour, single or initial drug)

**Note:** Include the JZ modifier if no amount of drug was discarded

### Box 24 E

Specify the diagnosis, from Box 21, that relates to the drug or procedure listed in Box 24 D

### Box 24 G

Enter the number of service units for each line item

### HEALTH INSURANCE CLAIM FORM

APPROVED BY NATIONAL UNIFORM CLAIM COMMITTEE (NUCC) 02/12

1. MEDICARE <input type="checkbox"/> MEDICAID <input type="checkbox"/> TRICARE <input type="checkbox"/> CHAMPVA <input type="checkbox"/> GROUP HEALTH PLAN <input type="checkbox"/> FECA BLK LONG <input type="checkbox"/> OTHER <input type="checkbox"/>												1a. INSURED'S I.D. NUMBER (For Program in Item 1)											
2. PATIENT'S NAME (Last Name, First Name, Middle Initial)												3. PATIENT'S BIRTH DATE MM DD YY		SEX M <input type="checkbox"/> F <input type="checkbox"/>		4. INSURED'S NAME (Last Name, First Name, Middle Initial)							
5. PATIENT'S ADDRESS (No., Street)												6. PATIENT RELATIONSHIP TO INSURED Self <input type="checkbox"/> Spouse <input type="checkbox"/> Child <input type="checkbox"/> Other <input type="checkbox"/>		7. INSURED'S ADDRESS (No., Street)									
CITY												STATE		CITY		STATE							
ZIP CODE												TELEPHONE (Include Area Code)		ZIP CODE		TELEPHONE (Include Area Code)							
9. OTHER INSURED'S NAME (Last Name, First Name, Middle Initial)												10. IS PATIENT'S CONDITION RELATED TO:		11. INSURED'S POLICY GROUP OR FECA NUMBER									
a. OTHER INSURED'S POLICY OR GROUP NUMBER												a. EMPLOYMENT? (Current or Previous) YES <input type="checkbox"/> NO <input type="checkbox"/>		a. INSURED'S DATE OF BIRTH MM DD YY		SEX M <input type="checkbox"/> F <input type="checkbox"/>							
b. RESERVED FOR NUCC USE												b. AUTO ACCIDENT? YES <input type="checkbox"/> NO <input type="checkbox"/>		b. OTHER CLAIM ID (Designated by NUCC)									
c. RESERVED FOR NUCC USE												c. OTHER ACCIDENT? YES <input type="checkbox"/> NO <input type="checkbox"/>		c. INSURANCE PLAN NAME OR PROGRAM NAME									
d. INSURANCE PLAN NAME OR PROGRAM NAME												10d. CLAIM CODES (Designated by NUCC)		d. IS THERE ANOTHER HEALTH BENEFIT PLAN? YES <input type="checkbox"/> NO <input type="checkbox"/>									
12. PATIENT'S OR AUTHORIZED PERSON'S SIGNATURE (I authorize the release of any medical or other information necessary to process this claim. I also request payment of government benefits either to myself or to the party who accepts assignment below.)												13. INSURED'S OR AUTHORIZED PERSON'S SIGNATURE (I authorize payment of medical benefits to the undersigned physician or supplier for services described below.)											
SIGNED _____ DATE _____												SIGNED _____ DATE _____											
14. DATE OF CURRENT ILLNESS, INJURY, OR PREGNANCY (LMP) 19 ____ QUAL. ____												15. OTHER DATE MM DD YY		16. DATES PATIENT UNABLE TO WORK IN CURRENT OCCUPATION FROM MM DD YY TO MM DD YY									
17. DATE OF REFERRING PROVIDER OR OTHER SOURCE 17a. ____ 17b. ____												18. HOSPITALIZATION DATES RELATED TO CURRENT SERVICES FROM MM DD YY TO MM DD YY		19. OUTSIDE LAB? YES <input type="checkbox"/> NO <input type="checkbox"/>									
19. ADDITIONAL CLAIM INFORMATION (Designated by NUCC)												20. OUTSIDE LAB? YES <input type="checkbox"/> NO <input type="checkbox"/>		21. RESUBMISSION CODE		22. PRIOR AUTHORIZATION							
21. DIAGNOSIS OR NATURE OF ILLNESS, INJURY, OR PREGNANCY (LMP) ZYNYZ (retifanlimab-dlwr), Infusion, 50881-006-03												22. RESUBMISSION CODE		23. ORIGINAL REF. NO.									
A. Diagnosis Code 24 A-B												B. DATE OF SERVICE 24 D		C. PLACE OF SERVICE 24 E		D. PROCEDURE(S), SERVICE(S), OR SUPPLIES 24 G							
24. A. DATE(S) OF SERVICE From MM DD YY To MM DD YY												B. PLACE OF SERVICE		C. PROCEDURE(S), SERVICE(S), OR SUPPLIES (Explain Unusual Circumstances) CPT/HCPCS		D. DIAGNOSIS POINTER		E. \$ CHARGES		F. DITS OR UNITS		G. H. I. J. K. L. M. N. O. P. Q. R. S. T. U. V. W. X. Y. Z.	
1 10 01 23 10 01 23 11 96413 A \$ 1 NPI												2 10 01 23 10 01 23 11 J9345 A \$ 1 NPI		3		4		5		6			
25. FEDERAL TAX I.D. NUMBER												26. PATIENT'S ACCOUNT NO.		27. ACCEPT ASSIGNMENT? YES <input type="checkbox"/> NO <input type="checkbox"/>		28. TOTAL CHARGE \$		29. AMOUNT PAID \$		30. Rvd for NUCC Use			
31. SIGNATURE OF PHYSICIAN OR SUPPLIER INCLUDING DEGREES OR CREDENTIALS (I certify that the statements on the reverse apply to this bill and are made a part thereof.)												32. SERVICE FACILITY LOCATION INFORMATION		33. BILLING PROVIDER INFO & PH #									
SIGNED _____ DATE _____												a. NPI b.		a. NPI b.									

NUCC Instruction Manual available at: [www.nucc.org](http://www.nucc.org)

## IMPORTANT SAFETY INFORMATION (CONT'D)

### Immune-Mediated Colitis

ZYNYZ can cause immune-mediated colitis. Cytomegalovirus infections/reactivations have occurred in patients with corticosteroid-refractory immune-mediated colitis treated with PD-1/PD-L1-blocking antibodies. In cases of corticosteroid-refractory colitis, consider repeating infectious workup to exclude alternative etiologies.

**ZYNYZ<sup>®</sup>**  
retifanlimab-dlwr  
Injection 500 mg

# Coverage, Coding, and Payment in the Hospital Outpatient Setting

For Medicare patients, ZYNYZ® (retifanlimab-dlwr) will be covered under Medicare Part B when used for an FDA-approved indication and when medically reasonable and necessary. There are no prior authorization requirements for ZYNYZ under traditional fee-for-service Medicare plans.

For patients enrolled in Medicaid, a Medicare Advantage plan, or a commercial health plan, coverage of ZYNYZ will vary by payer. Some payers may also apply utilization restrictions for ZYNYZ.

Incyte cannot guarantee payment of any claim and providers should contact third-party payers for specific information on their coding, coverage, and payment policies as needed.

**Please refer to the table below to support appropriate claims processing for ZYNYZ.**

MCC ICD-10-CM DIAGNOSIS CODES			
<b>C4A0</b>	Merkel cell carcinoma of lip	<b>C4A4</b>	Merkel cell carcinoma of scalp and neck
<b>C4A10</b>	Merkel cell carcinoma of unspecified eyelid, including canthus	<b>C4A51</b>	Merkel cell carcinoma of anal skin
<b>C4A111</b>	Merkel cell carcinoma of right upper eyelid, including canthus	<b>C4A52</b>	Merkel cell carcinoma of skin of breast
<b>C4A112</b>	Merkel cell carcinoma of right lower eyelid, including canthus	<b>C4A59</b>	Merkel cell carcinoma of other part of trunk
<b>C4A121</b>	Merkel cell carcinoma of left upper eyelid, including canthus	<b>C4A60</b>	Merkel cell carcinoma of unspecified upper limb, including shoulder
<b>C4A122</b>	Merkel cell carcinoma of left lower eyelid, including canthus	<b>C4A61</b>	Merkel cell carcinoma of right upper limb, including shoulder
<b>C4A20</b>	Merkel cell carcinoma of unspecified ear and external auricular canal	<b>C4A62</b>	Merkel cell carcinoma of left upper limb, including shoulder
<b>C4A21</b>	Merkel cell carcinoma of right ear and external auricular canal	<b>C4A70</b>	Merkel cell carcinoma of unspecified lower limb, including hip
<b>C4A22</b>	Merkel cell carcinoma of left ear and external auricular canal	<b>C4A71</b>	Merkel cell carcinoma of right lower limb, including hip
<b>C4A30</b>	Merkel cell carcinoma of unspecified part of face	<b>C4A72</b>	Merkel cell carcinoma of left lower limb, including hip
<b>C4A31</b>	Merkel cell carcinoma of nose	<b>C4A8</b>	Merkel cell carcinoma of overlapping sites
<b>C4A39</b>	Merkel cell carcinoma of other parts of face	<b>C4A9</b>	Merkel cell carcinoma, unspecified

  

ZYNYZ DRUG AND ADMINISTRATION CODES			
National Drug Code (NDC)	Drug Administration / CPT Codes	Modifier	HCPCS Code
10-digit: 50881-006-03 11-digit: 50881-0006-03	<b>96413</b> (Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial drug)	<b>JZ</b> (Modifier for recording zero product wastage)	<b>J9345</b> (Injection, retifanlimab-dlwr, 1 mg)

  

PAYMENT METHODOLOGY	
Medicare	Commercial Payers and Medicaid
Average Sales Price (ASP) +6% <sup>a</sup>	Most non-Medicare payers will pay separately for ZYNYZ; however payment rates will vary by payer and provider contract

<sup>a</sup> If Medicare sequestration is in effect, a statutory reduction to the payment is applied. Please visit CMS.gov for more information.  
OPPS, Outpatient Prospective Payment System.



# Coding and Billing Reference Guide

## Example CMS-1450 Claim Form - Hospital Outpatient Setting

This example form is provided for guidance and reference only.

ZYNYZ® (retifanlimab-dlwr) and the associated services provided in a hospital outpatient setting are billed on the CMS-1450 Claim Form or its electronic equivalent. An example CMS-1450 Claim Form is provided below. It is always the provider's responsibility to determine the appropriate healthcare setting, and to submit true and correct claims for the products and services rendered. **Incyte cannot guarantee payment of any claim and providers should contact third-party payers for specific information on their coding, coverage, and payment policies as needed.**

### Box 42

List the appropriate revenue code for each service provided. Drugs that are billed with HCPCS codes usually require revenue code 0636 (drugs requiring detailed coding)

### Box 43

For each item, enter the description of the revenue code used

### Box 44

Enter the appropriate HCPCS codes, for example:

- Drug - J9345 (Injection, retifanlimab-dlwr, 1 mg), effective 10/01/2023
- Administration - 96413 (chemo infusion for 1st hour, single or initial drug)

**Note:** Include the JZ modifier if no amount of drug was discarded

### Box 45

Enter the service date

### Box 46

Enter the number of service units for each line item

### Box 67

Enter the primary diagnosis code

### Box 80

Payers require drug name, route of administration, NDC, and total dosage. Check with your payer to verify specific requirements, including use of the 10-digit or 11-digit NDC

1		2		3a PAY ORIGIN # b MED NDC #		4 TYPE OF BILL	
8 PATIENT NAME		9 PATIENT ADDRESS		10 STATEMENT PERIOD FROM		11 STATEMENT PERIOD THROUGH	
12 BIRTHDATE		13 SEX		14 DATE		15 ADMISSION	
16 DHR		17 STAT		18		19	
20		21		22		23	
24		25		26		27	
28		29		30		31	
32		33		34		35	
36		37		38		39	
40		41		42		43	
44		45		46		47	
48		49		50		51	
52		53		54		55	
56		57		58		59	
60		61		62		63	
64		65		66		67	
68		69		70		71	
72		73		74		75	
76		77		78		79	
80		81		82		83	
84		85		86		87	
88		89		90		91	
92		93		94		95	
96		97		98		99	

42 REV. CD. 43 DESCRIPTION 44 HCPCS / RATE / HPCS CODE 45 SERV. DATE 46 SERV. UNITS 47 TOTAL CHARGES 48 NON-COVERED CHARGES 49

0335	Chemo Infusion Intravenous	96413	10012023	1	\$\$		
0636	Injection, retifanlimab-dlwr, 1 mg	J9345	10012023	1	\$\$		

PAGE 1 OF 1 CREATION DATE 10/01/2023 TOTALS

50 PAYER NAME 51 HEALTH PLAN ID 52 REL. INFO 53 ADD. INFO 54 PRIOR PAYMENTS 55 EST. AMOUNT DUE 56 NPI 57 OTHER PRV ID

58 INSURED'S NAME 59 FREL 60 INSURED'S UNIQUE ID 61 GROUP NAME 62 INSURANCE GROUP NO.

63 TREATMENT AUTHORIZATION CODES 64 DOCUMENT CONTROL NUMBER 65 EMPLOYER NAME

67 DX Code

68

69 ADMIT DX 70 PATIENT REASON DX 71 PRS CODE 72 EDC 73

74 PRINCIPAL PROCEDURE CODE DATE 75 OTHER PROCEDURE CODE DATE 76 OTHER PROCEDURE CODE DATE 77 OTHER PROCEDURE CODE DATE 78 OTHER PROCEDURE CODE DATE 79 OTHER PROCEDURE CODE DATE 80 OTHER PROCEDURE CODE DATE

80 REMARKS  
ZYNYZ (retifanlimab-dlwr), Infusion  
50881-006-03

81CIC a b c d

82CIC a b c d

83CIC a b c d

84CIC a b c d

85CIC a b c d

86CIC a b c d

87CIC a b c d

88CIC a b c d

89CIC a b c d

90CIC a b c d

91CIC a b c d

92CIC a b c d

93CIC a b c d

94CIC a b c d

95CIC a b c d

96CIC a b c d

97CIC a b c d

98CIC a b c d

99CIC a b c d

## IMPORTANT SAFETY INFORMATION (CONT'D)

Immune-mediated colitis occurred in 1.6% (7/440) of patients, including Grade 4 (0.2%), Grade 3 (0.2%), and Grade 2 (0.7%). Colitis led to permanent discontinuation of ZYNYZ in 1 patient and withholding in 0.9%.

Systemic corticosteroids were required in 71% (5/7) of patients. Colitis resolved in 4/7 patients.

**ZYNYZ**<sup>®</sup>  
retifanlimab-dlwr  
Injection 500 mg



# Provider Readiness—Process and Tips

When preparing to treat a patient with ZYNYZ® (retifanlimab-dlwr) as prescribed, consider the steps below to facilitate patient access, proper claims submission, and appropriate reimbursement. For questions or support on any of these steps, please reach out to IncyteCARES at **1-855-452-5234** or visit [HCP.IncyteCARES.com/ZYNYZ](https://HCP.IncyteCARES.com/ZYNYZ) to complete an Enrollment Form.

- 1 — **Research and understand** patient-specific benefits and coverage for ZYNYZ
- 2 — If there are access concerns, be sure to **enroll your patient** in IncyteCARES to understand potential financial assistance options that may be available for eligible patients
- 3 — **Schedule the patient** for his or her first ZYNYZ infusion
- 4 — **Purchase ZYNYZ** (if not already in inventory) through one of the following Specialty Distributors:



Prescribers who do not wish to use buy-and-bill should check with their preferred Specialty Pharmacy for availability. Specialty Pharmacies may obtain access to ZYNYZ through the Specialty Distributors listed above

- 5 — After treatment, **complete and submit a claim** to the payer, including all necessary information. If no product was discarded, include the JZ modifier to attest to no wastage

## IMPORTANT SAFETY INFORMATION (CONT'D)

### Immune-Mediated Hepatitis

ZYNYZ can cause immune-mediated hepatitis. Immune-mediated hepatitis occurred in 3% (13/440) of patients, including Grade 4 (0.2%), Grade 3 (2.3%), and Grade 2 (0.5%). Hepatitis led to permanent discontinuation of ZYNYZ in 1.4% of patients and withholding in 0.9%.

Systemic corticosteroids were required in 85% (11/13) of patients. Hepatitis resolved in 6/13 patients.

### Immune-Mediated Endocrinopathies

#### *Adrenal Insufficiency*

ZYNYZ can cause primary or secondary adrenal insufficiency. For  $\geq$  Grade 2 adrenal insufficiency, initiate symptomatic treatment per institutional guidelines, including hormone replacement as clinically indicated. Withhold or permanently discontinue ZYNYZ depending on severity.



Contact IncyteCARES at  
**1-855-452-5234** or  
[HCP.IncyteCARES.com/ZYNYZ](https://HCP.IncyteCARES.com/ZYNYZ)





## We're Here to Support Your Eligible Patients During Treatment

Our mission is to help your patients start and stay on therapy by assisting with access and as-needed support.

## When You Enroll a Patient, an IncyteCARES Representative Will:

- Call your patient to welcome them and explain their insurance coverage for ZYNYZ® (retifanlimab-dlwr)
- Assess patient's eligibility for savings or financial assistance programs,\* and help them enroll
- Explain the additional support and resources available to them during treatment

\* Terms and conditions apply. Program terms may change at any time.



*For Eligible Patients With Commercial Health Insurance*

### **IncyteCARES for ZYNYZ Savings Program**

**Eligible patients can receive ZYNYZ for as little as \$15, subject to certain limits†**

#### **To qualify, patients must:**

- Have commercial healthcare coverage. Patients insured under federal or state government healthcare programs—including Medicare Part B, Medicare Advantage, Medicaid, TRICARE or any state medical or pharmaceutical assistance program—are not eligible. Patients without healthcare coverage are also not eligible
- Be a resident of the United States or Puerto Rico
- Have a valid prescription for ZYNYZ for an FDA-approved use

† Uninsured, cash-paying, or Alternate Funding Program (AFP) patients are not eligible. Not valid for patients insured through Medicare Part B, Medicare Advantage, Medicaid, TRICARE, or any state medical or pharmaceutical assistance program. Patient enrollment in a copay adjustment program, such as a maximizer or accumulator program, may impact the value of this offer. Annual benefit maximum applies, as may other restrictions. Program benefit applies to medication cost only and does not cover any costs to administer the medication. Valid prescription for ZYNYZ® (retifanlimab-dlwr) for an FDA-approved indication or compendia-recognized use is required. Please see the full [Patient Terms and Conditions](#) or call IncyteCARES for ZYNYZ at **1-855-452-5234**. Update effective as of January 1, 2024.

## IMPORTANT SAFETY INFORMATION (CONT'D)

Adrenal insufficiency occurred in 0.7% (3/440) of patients, including Grade 3 (0.5%) and Grade 2 (0.2%). ZYNYZ was permanently discontinued in no patients and was withheld for 1 patient with adrenal insufficiency. All patients required systemic corticosteroids. Adrenal insufficiency resolved in 1 of the 3 patients.

### *Hypophysitis*

ZYNYZ can cause immune-mediated hypophysitis. Hypophysitis can present with acute symptoms associated with mass effect such as headache, photophobia, or visual field cuts, and can cause hypopituitarism. Initiate hormone replacement as clinically indicated. Withhold or permanently discontinue ZYNYZ depending on severity.

Hypophysitis occurred in 0.5% (2/440, both Grade 2) of patients. No patients discontinued or withheld ZYNYZ due to hypophysitis.

All patients required systemic steroids. Hypophysitis resolved in 1 of the 2 patients.

**ZYNYZ<sup>®</sup>**  
retifanlimab-dlwr  
Injection 500 mg

## Enroll Your Eligible Patients in IncyteCARES for ZYNYZ® (retifanlimab-dlwr)

Completing the enrollment form takes about 15 minutes. Simply download, complete, and fax it. Visit [HCP.IncyteCARES.com/ZYNYZ](https://HCP.IncyteCARES.com/ZYNYZ) for more information.

## Other Financial Assistance and Support Options

When you enroll your patient in IncyteCARES for ZYNYZ, we will also review their eligibility for the following programs.



*For Eligible Patients Who Are Uninsured or Underinsured for ZYNYZ*

### **IncyteCARES for ZYNYZ Patient Assistance Program**



*For All Patients*

### **Information About Nonprofit or Other Support Organizations**



### **Questions?**

Call IncyteCARES for ZYNYZ at **1-855-452-5234**,  
Monday through Friday, 8 AM - 8 PM ET

Please see [HCP.IncyteCARES.com/ZYNYZ](https://HCP.IncyteCARES.com/ZYNYZ) for full program terms and conditions.

## **IMPORTANT SAFETY INFORMATION (CONT'D)**

### *Thyroid Disorders*

ZYNYZ can cause immune-mediated thyroid disorders. Thyroiditis can present with or without endocrinopathy. Hypothyroidism can follow hyperthyroidism. Initiate hormone replacement or medical management of hyperthyroidism as clinically indicated. Withhold or permanently discontinue ZYNYZ depending on severity.

Thyroiditis occurred in 0.7% (3/440, all Grade 1) of patients. No patients discontinued or withheld ZYNYZ due to thyroiditis. Thyroiditis resolved in 1 of the 3 patients.

### *Hypothyroidism*

Hypothyroidism occurred in 10% (42/440) of patients receiving ZYNYZ, including Grade 2 (4.8%). No patients discontinued due to hypothyroidism. ZYNYZ was withheld in 0.5% of patients.

Systemic corticosteroids were required for 1 patient, and 79% (33/42) of patients received endocrine therapy.

**ZYNYZ<sup>®</sup>**  
retifanlimab-dlwr  
Injection 500 mg

# IMPORTANT SAFETY INFORMATION (CONT'D)

## *Hyperthyroidism*

Hyperthyroidism occurred in 6% (24/440) of patients receiving ZYNYZ® (retifanlimab-dlwr), including Grade 2 (2.5%). ZYNYZ was not discontinued in any patient and was withheld in 1 patient. Systemic corticosteroids were required for 13% (3/24) of patients, and 46% (11/24) of patients received endocrine therapy.

## *Type 1 Diabetes Mellitus, Which Can Present with Diabetic Ketoacidosis*

Monitor patients for hyperglycemia or other signs and symptoms of diabetes. Initiate treatment with insulin as clinically indicated. Withhold ZYNYZ depending on severity.

Type 1 diabetes mellitus occurred in 0.2% (1/440) of patients, including Grade 3 (0.2%) adverse reactions.

## Immune-Mediated Nephritis with Renal Dysfunction

ZYNYZ can cause immune-mediated nephritis. Immune-mediated nephritis occurred in 1.6% (7/440) of patients receiving ZYNYZ, including Grade 4 (0.5%), Grade 3 (0.7%), and Grade 2 (0.5%). Nephritis led to permanent discontinuation of ZYNYZ in 0.9% of patients and withholding in 1 patient.

Systemic corticosteroids were required in 57% (4/7) of patients. Nephritis resolved in 3/7 patients.

## Immune-Mediated Dermatologic Adverse Reactions

ZYNYZ can cause immune-mediated rash or dermatitis. Bullous and exfoliative dermatitis, including Stevens-Johnson syndrome, drug rash with eosinophilia and systemic symptoms, and toxic epidermal necrolysis, has occurred with PD-1/PD-L1-blocking antibodies. Topical emollients and/or topical corticosteroids may be adequate to treat mild to moderate non-exfoliative rashes. Withhold or permanently discontinue ZYNYZ depending on severity.

Immune-mediated skin reactions occurred in 8% (36/440) of patients, including Grade 3 (1.1%) and Grade 2 (7%). Immune-mediated dermatologic adverse reactions led to permanent discontinuation of ZYNYZ in 1 patient and withholding in 2.3% of patients.

Systemic corticosteroids were required in 25% (9/36) of patients. Immune-mediated dermatologic adverse reactions resolved in 75% (27/36) of patients.

## Other Immune-Mediated Adverse Reactions

The following clinically significant immune-mediated adverse reactions occurred at an incidence of < 1% in 440 patients who received ZYNYZ or were reported with the use of other PD-1/PD-L1-blocking antibodies, including severe or fatal cases.

*Cardiac/vascular:* myocarditis, pericarditis, vasculitis

*Gastrointestinal:* pancreatitis, to include increases in serum amylase and lipase levels, gastritis, duodenitis

*Musculoskeletal:* myositis/polymyositis, rhabdomyolysis (and associated sequelae, including renal failure), arthritis, polymyalgia rheumatica

*Neurological:* meningitis, encephalitis, myelitis and demyelination, myasthenic syndrome/myasthenia gravis (including exacerbation), Guillain-Barré syndrome, nerve paresis, autoimmune neuropathy

*Ocular:* uveitis, iritis, and other ocular inflammatory toxicities. Some cases can be associated with retinal detachment. Various grades of visual impairment to include blindness can occur. If uveitis occurs in combination with other immune-mediated adverse reactions, consider a Vogt-Koyanagi-Harada-like syndrome, as this may require treatment with systemic steroids to reduce the risk of permanent vision loss.

*Endocrine:* hypoparathyroidism

*Other (Hematologic/Immune):* hemolytic anemia, aplastic anemia, hemophagocytic lymphohistiocytosis, systemic inflammatory response syndrome, histiocytic necrotizing lymphadenitis (Kikuchi lymphadenitis), sarcoidosis, immune thrombocytopenic purpura, solid organ transplant rejection, other transplant (including corneal graft) rejection.

## Infusion-Related Reactions

A severe infusion-related reaction (Grade 3) occurred in 1 (0.2%) of 440 patients. Monitor patients for signs and symptoms; interrupt or slow the rate of infusion or permanently discontinue ZYNYZ based on severity of reaction. Consider premedication with an antipyretic and/or an antihistamine for patients who have had previous systemic reactions to infusions of therapeutic proteins.

**ZYNYZ<sup>®</sup>**  
retifanlimab-dlwr  
Injection 500 mg

# IMPORTANT SAFETY INFORMATION (CONT'D)

## Complications of Allogeneic HSCT

Fatal and other serious complications can occur in patients who receive allogeneic hematopoietic stem cell transplantation (HSCT) before or after being treated with a PD-1/PD-L1-blocking antibody. Transplant-related complications include hyperacute graft-versus-host disease (GVHD), acute GVHD, chronic GVHD, hepatic veno-occlusive disease after reduced intensity conditioning, and steroid-requiring febrile syndrome (without an identified infectious cause), which may occur despite intervening therapy between PD-1/PD-L1 blockade and allogeneic HSCT. Follow patients closely for evidence of transplant-related complications and intervene promptly. Consider the benefit versus risks of treatment with a PD-1/PD-L1-blocking antibody prior to or after an allogeneic HSCT.

## Embryo-Fetal Toxicity

ZYNYZ® (retifanlimab-dlwr) can cause fetal harm when administered to a pregnant woman. Animal studies have demonstrated that inhibition of the PD-1/PD-L1 pathway can lead to increased risk of immune-mediated rejection of the developing fetus, resulting in fetal death. Advise women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment and for 4 months after the last dose.

## Lactation

Because of the potential for serious adverse reactions in breastfed children, advise women not to breastfeed during treatment and for 4 months after the last dose.

## Adverse Reactions

The safety of ZYNYZ was evaluated in 105 patients with metastatic or recurrent locally advanced MCC. Serious adverse reactions occurred in 22% of patients receiving ZYNYZ. The most frequent serious adverse reactions ( $\geq 2\%$  of patients) were fatigue, arrhythmia, and pneumonitis.

Permanent discontinuation of ZYNYZ due to an adverse reaction occurred in 11% of patients. These included asthenia, atrial fibrillation, concomitant disease progression of chronic lymphocytic leukemia, demyelinating polyneuropathy, eosinophilic fasciitis, increased transaminases, infusion-related reaction, lung disorder, pancreatitis, polyarthrititis, and radiculopathy (1 patient each).

Dosage interruptions due to an adverse reaction occurred in 25% of patients. Adverse reactions or laboratory abnormalities that required dosage interruption in  $\geq 2\%$  of patients were increased transaminases, increased lipase, increased amylase, pneumonitis, and pyrexia.

The most common ( $\geq 10\%$ ) adverse reactions were fatigue, musculoskeletal pain, pruritus, diarrhea, rash, pyrexia, and nausea.

**You may report side effects to the FDA at (800) FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch). You may also report side effects to Incyte Corporation at 1-855-463-3463.**

**Please see the full Prescribing Information for ZYNYZ for additional Important Safety Information.**

**ZYNYZ<sup>®</sup>**  
retifanlimab-dlwr  
Injection 500 mg

**ZYNYZ**<sup>®</sup>  
retifanlimab-dlwr  
Injection 500 mg



ZYNYZ and the ZYNYZ logo are registered trademarks of Incyte.  
Incyte and the Incyte logo are registered trademarks of Incyte.  
All other trademarks are the property of their respective owners.  
© 2024, Incyte. MAT-RET-00191 06/24